{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.1","value":"5.48"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Apparent volume of distribution, calculated as \\[(CL/F)/λz\\].","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received intravenous daratumumab at 16 mg/kg on the same dosing schedule (weekly, every 2 weeks, or every 4 weeks of each 28-day treatment cycle) on their last prior therapy containing daratumumab regimen. The dosing schedule for daratumumab could be adjusted during the course of the study, provided the participant had a response of stable disease or better. Participants also received IV durvalumab at 1500 mg on Day 2 of Cycle 1 and then on Day 1 of Cycles ≥ 2 of each 28-day treatment cycle. Participants could continue on study treatment until progressive disease or unacceptable toxicity.","id":"OG000","title":"Daratumumab and Durvalumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The pharmacokinetic population included participants who received at least 1 dose of study medication and had evaluable plasma PK durvalumab profiles.","reportingStatus":"POSTED","timeFrame":"Pharmacokinetic samples were drawn on Cycle 1 on Day 2 (C1D2) pre-dose, at the end of the infusion, on Day 8 at 144 hour post dose, on Day 15 at 312 hours post dose and on Day 22 at 480 hours post C1D2 infusion.","title":"Apparent Volume of Distribution (Vz/F) of Durvalumab","type":"SECONDARY","unitOfMeasure":"Liters"}